Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.09, $0.01 better than the analyst estimate of $0.08. Revenue for the quarter came in at $29.6 million versus the consensus estimate of $29.48 million.

“Despite operating under COVID-19 conditions, I am quite pleased with the resiliency of our team and the operating results that were achieved during the second quarter. Additionally, as physicians’ practices begin to open again to in-person meetings with patients and sales representatives, we are beginning to see an improvement in new LEMS patient enrollments in Catalyst Pathways and are hopeful that this is a start of a trend,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. “On a separate note, we are disappointed that the top-line results of our Phase 3 study for Firdapse® in anti-MuSK antibody positive myasthenia gravis patients did not replicate the robust positive results that were observed in the 2017 proof-of-concept study. We intend to continue to analyze the data and meet with our neuromuscular key opinion leaders to decide on our path forward for this program.”

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.